Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study

Remdesivir is a drug widely used for the etiotropic treatment of COVID-19. According to a number of studies, the incidence of adverse reactions during remdesivir therapy reaches 66%, with the most common is an increase in liver function tests.The aim of the work was to study the influence of clinica...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yu. V. Shevchuk, A. V. Kryukov, I. I. Temirbulatov, I. V. Sychev, K. B. Mirzaev, N. P. Denisenko, Sh. P. Abdullaev, S. N. Tuchkova, V. I. Vechorko, O. V. Averkov, D. A. Sychev
Format:	Article
Language:	Russian
Published:	Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2023-11-01
Series:	Фармация и фармакология (Пятигорск)
Subjects:	covid-19 remdesivir hepatotoxicity adverse reactions predictors of adverse reactions pharmacogenetic study clinical trial
Online Access:	https://www.pharmpharm.ru/jour/article/view/1355
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Model for predicting risk of developing drug-induced liver injury during remdesivir therapy: observational prospective open case-control study

Similar Items